The first clinical case of dry age-related macular degeneration treated with photobiomodulation and nutraceuticals: a protocol proposal

CellR4 2020; 8: e2833
DOI: 10.32113/cellr4_20204_2833

  Topic: Age-related macular degeneration     Category:

Abstract

The purpose of this protocol proposal is to suggest a new non-invasive combined therapeutic approach for dry age-related macular degeneration (AMD), an eye disease with no approved treatment or cure. A nutraceutical approach involving dietary supplementation of antioxidants can reduce its risk. Also, photobiomodulation (PBM, or LLLT) has shown promising results with the advantage of non-invasiveness. We present a clinical case study which combines a nutraceutical approach with photobiomodulation. Nine PBM cycles were administered to the patient over one month, and lutein, resveratrol and Vaccinium myrtillus supplements for three months. After one month and after six months, the OCT showed reduced drusen. The patient obtained subjectively improved vision, less eye strain, more color contrast, higher definition and a better far and near uncorrected visual acuity. Amsler grid test was regular. Contrast sensitivity improved from 1.8 to 2.0. Outcomes remained stable at the 6-month follow-up.

This case demonstrated a successful non-invasive treatment with improved quality of vision in dry AMD. A larger population followed over a long-term period is warranted. Irradiation, along with the support of nutraceuticals, could therefore offer a new non-invasive, adverse-effect-free means of stimulating retinal stem cells to regenerate.

To cite this article

The first clinical case of dry age-related macular degeneration treated with photobiomodulation and nutraceuticals: a protocol proposal

CellR4 2020; 8: e2833
DOI: 10.32113/cellr4_20204_2833

Publication History

Submission date: 31 Mar 2020

Revised on: 03 Apr 2020

Accepted on: 09 Apr 2020

Published online: 16 Apr 2020